Myasthenia Gravis Induced by Immune Checkpoint Inhibitors: An Emerging Neurotoxicity in Neuro-Oncology Practice: Case Series

Immunotherapy with immune checkpoint inhibitors (ICIs) have been reported to induce de novo or exacerbate pre-existing Myasthenia Gravis (MG). We present a single center case series of patients who developed an immune-related myasthenia gravis (irMG) related with ICIs. We performed a retrospective c...

Full description

Saved in:
Bibliographic Details
Published inJournal of clinical medicine Vol. 12; no. 1; p. 130
Main Authors Marco, Carla, Simó, Marta, Alemany, Montse, Casasnovas, Carlos, Domínguez, Raúl, Vilariño, Noelia, Calvo, Mariona, Martín-Liberal, Juan, Brenes, Jesús, Sabater-Riera, Joan, Bruna, Jordi, Velasco, Roser
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 24.12.2022
MDPI
Subjects
Antibodies
Cancer therapies
Clinical medicine
Electromyography
FDA approval
Guillain-Barre syndrome
Immune system
Inflammatory diseases
Laboratories
Musculoskeletal diseases
Myasthenia gravis
Myocarditis
Neuromuscular diseases
Oncology
Patients
Steroids
myasthenia gravis
neurotoxicity
immune checkpoint inhibitors
neuro-oncology
immune-related adverse events
Online AccessGet full text

Cover

More Information
Summary:Immunotherapy with immune checkpoint inhibitors (ICIs) have been reported to induce de novo or exacerbate pre-existing Myasthenia Gravis (MG). We present a single center case series of patients who developed an immune-related myasthenia gravis (irMG) related with ICIs. We performed a retrospective chart review of the electronic medical records between 1 September 2017 and 2022. We report the clinical features, presentation forms, diagnostic workflows, general management and outcomes of six patients who received ICIs for different solid organ malignancies and developed an irMG frequently overlapping with immune-related myocarditis and/or myositis. The aim of the article is to describe the clinical features, treatment and outcomes of this challenging and potentially life-threating syndrome, comparing our data with those described in the literature. Differences between irMG and classic MG are highlighted.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2077-0383
2077-0383
DOI:10.3390/jcm12010130